On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study-Reference-Cited by-同舟云学术

On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study

Published:2017-03-02 Issue:8 Volume:45 Page:1146-1155
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Howell J.¹²³^ORCID,Pinato D. J.¹,Ramaswami R.¹,Bettinger D.⁴,Arizumi T.⁵,Ferrari C.⁶,Yen C.¹,Gibbin A.⁶,Burlone M. E.⁶,Guaschino G.⁶,Sellers L.¹,Black J.¹,Pirisi M.⁵,Kudo M.⁵,Thimme R.⁴,Park J.-W.⁷,Sharma R.¹

Affiliation:

1. Department of Surgery and Cancer; Imperial College London; Hammersmith Hospital; London UK

2. Department of Medicine; University of Melbourne; St Vincent's Hospital; Melbourne Vic. Australia

3. Centre for Population Health; Macfarlane-Burnet Institute; Melbourne Vic. Australia

4. Department of Medicine II; University Hospital Freiburg; Freiburg Germany

5. Department of Gastroenterology and Hepatology; Kindai University School of Medicine; Osaka-Sayama Osaka Japan

6. Department of Translational Medicine; Università degli Studi del Piemonte Orientale “A. Avogadro”; Novara Italy

7. Center for Liver Cancer; National Cancer Center; Goyang Gyeonggi South Korea

Funder

National Medical Research Council

National Institute for Health Research

Berta-Ottenstein-Programme

Albert-Ludwigs-Universität Freiburg

Academy of Medical Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13977/fullpdf

Reference37 articles.

1. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012;Ferlay;Int J Cancer,2015

2. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

3. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma;Abou-Alfa;J Clin Oncol,2006

4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial;Cheng;Lancet Oncol,2009

5. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib;Reig;J Hepatol,2014

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab;Targeted Oncology;2024-04-30

2. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma;Alimentary Pharmacology & Therapeutics;2024-04-21

3. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours;Journal of Hepatology;2023-11

4. HDACIs and TKIs combinations and their liposomal delivery for cancer treatment;Journal of Controlled Release;2023-06

5. A case of multiple hepatocellular carcinoma experiencing complete responses to sorafenib and atezolizumab–bevacizumab and developing severe, refractory venous congestive cutaneous ulcers on either regimen;Clinical Journal of Gastroenterology;2023-01-09